Annovis Bio, Inc. Common Stock (ANVS)

Annovis Bio (NYSE: ANVS) announced it will initiate an open-label extension study in January 2026 to further evaluate the long-term safety and efficacy of buntanetap in patients with Parkinson disease. The study will provide continued access to buntanetap for participants from prior clinical trials while enabling extended monitoring of safety outcomes, sustained effects on motor and cognitive function, and the collection of biomarker data to support further evaluation of buntanetap’s potential as a disease-modifying therapy for neurodegenerative disorders.

Enrollment will begin in January 2026

Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company developing therapies for neurodegenerative diseases including Alzheimer disease and Parkinson disease, will host a corporate update webinar followed by a live question-and-answer session. The webinar will feature President and Chief Executive Officer Maria Maccecchini, Ph.D., who will provide an overview of recent company progress, ongoing clinical programs and strategic direction.

MALVERN, Pa., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced it will host a corporate update webinar followed by a live Q&A session.

Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company developing therapies for neurodegenerative diseases including Alzheimer’s disease and Parkinson’s disease, said it will present at the 2025 Annual Meeting of the Parkinson Study Group, held Dec. 4–6 in San Diego. The presentation will expand on recent Phase 3 Parkinson’s biomarker results showing that patients with amyloid co-pathology experience more severe cognitive decline that is reversed by buntanetap, which also reduces tau biomarkers linked to disease progression. Annovis will also debut a cross-study comparison of all completed trials, offering the most comprehensive view to date of cognitive outcomes across indications and underscoring that patients with amyloid pathology achieve the greatest cognitive benefit, supporting the Company’s strategic path forward.

MALVERN, Pa., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced it will present at the 2025 Annual Meeting of the Parkinson Study Group (PSG), taking place December 4-6, 2025 in San Diego, California.

MALVERN, Pa., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced two presentations at the 18th Clinical Trials on Alzheimer's Disease (CTAD) conference, taking place December 1-4, 2025 in San Diego, California.

Annovis Bio (NYSE: ANVS) a late-stage clinical drug platform company developing therapies for neurodegenerative diseases including Alzheimer’s and Parkinson’s, announced that the FDA has scheduled a Type C meeting in January 2026 to discuss the clinical pathway for buntanetap in Parkinson’s disease dementia. The Company also reaffirmed continued progress in its Phase 3 Alzheimer’s trial, which remains in full regulatory alignment on design, endpoints and patient population. CEO Maria Maccecchini said the meeting marks an important milestone for the PDD program, with Senior VP Cheng Fang noting that strong data across Alzheimer’s and Parkinson’s studies highlights buntanetap’s potential to address a major unmet need for cognitive decline in Parkinson’s patients.

EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:RXRX),(NASDAQ:NTLA),(NASDAQ:ZYME),(NYSE:ANVS) EQNX::TICKER_END

MarketNewsUpdates News Commentary

MALVERN, Pa., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced that the U.S. Food and Drug Administration (FDA) has scheduled a Type C meeting in January 2026 to discuss the Company's pathway for Parkinson's disease dementia (PDD). Annovis also reaffirmed that its ongoing Phase 3 AD clinical trial continues to progress with full regulatory alignment on study design, endpoints, and patient population.

Annovis Bio (NYSE: ANVS) released new findings from its Phase 3 early Parkinson’s disease study showing that buntanetap halted cognitive decline across all patients and delivered the strongest benefit in those with mild dementia and amyloid co-pathology, a group representing about 25% of the study population. These patients typically experience faster cognitive deterioration, but treatment with buntanetap reversed this decline and produced measurable reductions in pTau217, total tau and brain-derived tau—biomarkers associated with Alzheimer’s pathology. Annovis noted that the data reinforce its view that neurodegenerative diseases often overlap and require therapies capable of targeting multiple toxic proteins, positioning buntanetap as a potentially broad-acting treatment for cognitive impairment across Parkinson’s and Alzheimer’s disease biology.

Buntanetap significantly improves cognition in all Parkinson’s patients, with those exhibiting Alzheimer’s co-pathology showing a three-times greater response

NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, announced it will release its third quarter 2025 financial results before market open on Monday, Nov. 17, 2025, followed by a conference call at 8:30 a.m. ET to discuss corporate, financial, and operational updates.

Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company developing therapies for neurodegenerative diseases including Alzheimer’s and Parkinson’s, reported significant third quarter 2025 progress, led by full activation of all 84 sites in its pivotal Phase 3 Alzheimer’s study (NCT06709014) and steady enrollment across the U.S. The company also announced promising biomarker data from its Phase 2/3 Alzheimer’s trial showing strong reductions in inflammation and neurodegeneration, underscoring buntanetap’s disease-modifying potential. Recent achievements include transferring all patents to the new crystal form of buntanetap with IP protection through 2046, publishing supportive pharmacokinetic data, and appointing veteran finance executive Mark Guerin as CFO. “Every element is now aligned as we move toward our data readouts—the final step before an NDA submission,” said Maria Maccecchini, Ph.D., president and CEO.

MALVERN, Pa., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today provided corporate updates and third quarter 2025 financial results.

Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company developing therapies for neurodegenerative diseases including Alzheimer’s and Parkinson’s, announced that all 84 U.S. sites for its pivotal Phase 3 trial in early Alzheimer’s disease are now fully activated and enrolling, with most already treating patients. The first group of participants has completed the 6-month treatment phase, keeping the company on schedule to deliver symptomatic data in the second half of 2026. CEO Maria Maccecchini said the study, now 25% complete, reflects strong execution and continued momentum toward bringing buntanetap to patients in need of effective therapies.

All 84 clinical sites across the U.S. are fully activated, enrolling, and treating patients

Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company developing therapies for neurodegenerative diseases including Alzheimer’s and Parkinson’s, entered definitive agreements for a registered direct offering of 1,670,732 shares of common stock at $2.05 per share, reflecting the Oct. 24 closing price. The $3.4 million offering, led by H.C. Wainwright & Co. as exclusive placement agent, includes participation from Chairman Michael Hoffman and CEO Dr. Maria Maccecchini. Closing is expected on or about Oct. 28, 2025, with proceeds earmarked for working capital and general corporate purposes.

MALVERN, Pa., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), today announced that it has entered into definitive agreements, with the participation of Michael Hoffman, the Chairman of the Company’s board of directors, and Dr. Maria Maccecchini, the Company’s Chief Executive Officer, for the purchase of an aggregate of 1,670,732 shares of its common stock at a purchase price of $2.05 per share, which was the closing price of the common stock on NYSE on October 24, 2025, in a registered direct offering. The closing of the offering is expected to occur on or about October 28, 2025, subject to the satisfaction of customary closing conditions.

Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company developing therapies for neurodegenerative diseases including Alzheimer’s and Parkinson’s, closed its previously announced registered direct offering of 4 million shares of common stock (or pre-funded warrants) at $1.50 per share. H.C. Wainwright & Co. served as exclusive placement agent. Gross proceeds totaled approximately $6 million before fees and expenses, with net proceeds intended for working capital and general corporate purposes.

MALVERN, Pa., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), today announced the closing of its previously announced registered direct offering for the purchase of an aggregate of 4,000,000 shares of its common stock (or pre-funded warrants in lieu thereof) at a purchase price of $1.50 per share (or pre-funded warrant in lieu thereof).

MALVERN, Pa., Oct. 10, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), today announced that it has entered into definitive agreements for the purchase of an aggregate of 4,000,000 shares of its common stock (or pre-funded warrants in lieu thereof) at a purchase price of $1.50 per share (or pre-funded warrant in lieu thereof) in a registered direct offering. The closing of the offering is expected to occur on or about October 13, 2025, subject to the satisfaction of customary closing conditions.

Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company developing therapies for neurodegenerative diseases including Alzheimer’s and Parkinson’s, announced new results showing that buntanetap reduced key inflammatory biomarkers and improved neuronal integrity in Alzheimer’s patients. Data from the Phase 2/3 study demonstrated lower levels of IL-5, IL-6, S100A12, IFN-γ, and IGF1R in treated patients versus placebo, along with reduced neurofilament light chain (NFL), suggesting improved cellular health and potential disease-modifying effects. CEO Maria Maccechini said the findings confirm buntanetap’s multi-targeted mechanism and validate earlier preclinical and clinical results, advancing confidence in its potential to deliver meaningful therapeutic benefit.

MALVERN, Pa., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced new results that demonstrate buntanetap’s ability to attenuate inflammation and improve cellular health in Alzheimer’s patients, suggesting potential disease-modifying effects beyond symptomatic relief.